Incanthera plc - Admission to trading on NEX

RNS Number : 4137E

Immupharma PLC

28 February 2020

 

28 February 2020

ImmuPharma PLC

("ImmuPharma" or the "Company")

Incanthera plc - Admission to trading on the NEX Exchange Growth Market
Publication of Admission Document

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM), a specialist drug discovery and development company, notes that further to its announcement on 17 February 2020,  Incanthera plc ("Incanthera"), a specialist oncology company, has today been admitted to the NEX Exchange Growth Market (TIDM: INC) and has published its Admission Document.

Following Admission to trading, ImmuPharma retains 7,272,740 ordinary shares in Incanthera, representing 11.9% of Incanthera's enlarged issued ordinary share capital. As for all Incanthera's major shareholders, ImmuPharma has entered a standard "lock-in" agreement for these shares, for a period up to 12 months following Admission.

ImmuPharma also has 7,272,740 warrants at an exercise price of 9.5p pence, being the price at which new shares have been issued in the Placing accompanying Incanthera's listing ("Issue Price").

In addition, ImmuPharma has entered into a Subscription Agreement with Incanthera. Under the Subscription Agreement, ImmuPharma has the right, at any time prior to 31 October 2020, to subscribe for 2,631,579 new Ordinary Shares in Incanthera at the Issue Price (an amount of £250,000). Should ImmuPharma not exercise their right to subscribe by 31 October 2020, Incanthera may serve notice to ImmuPharma requiring exercise within 10 business days

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

For further information please contact: ImmuPharma PLC ( www.immupharma.com ) Tim McCarthy, Chairman + 44 (0) 207 152 4080 Dimitri Dimitriou, Chief Executive Officer Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin/Henry Todd Stanford Capital Partners (Joint Broker) Patrick Claridge, John Howes SI Capital (Joint Broker) Nick Emerson [phone] [phone] [phone] 4Reliance (Euronext Growth Listing Sponsor) Jean-Charles Snoy Degroof Petercam (Liquidity Provider) Erik De Clippel Backstage Communication Olivier Duquaine Jean-Louis Dubrule [phone] [phone] [phone] [phone]

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 29 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.com .

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

About Incanthera plc

Incanthera plc was formed in 2010 as a spin-out from the Institute of Cancer Therapeutics at Bradford University and is targeting the treatment of cancer through a portfolio of unique technologies. Having successfully commercialised its lead product in 2017, it is further developing its portfolio of cancer therapeutics.

For additional information about Incanthera and to access the Admission Document, please visit www.incanthera.com .

Incanthera's share price can be accessed via the company's website, as above, or via the investors page on the NEX Exchange website, www.nexexchange.com.

Incanthera's LEI code: 2138002HEV4UFBOEXQ97 and ISIN number GB00BGL7YW15.

 

END

 

 

MSCEAXAXAANEEFA